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Protocol
AbstrACt
Introduction Diagnosis of endoleaks is imperative 
to prevent failure of endovascular aneurysm repairs 
(EVARs). The gold standard for diagnosis of endoleaks is 
catheter-directed subtraction angiography, which is not 
a practicable choice for surveillance. CT angiography 
(CTA) is the historical surveillance modality of choice. 
Concerns over cost, potential nephrotoxicity of contrast 
agents and repeated radiation exposure led to colour 
duplex ultrasound scan (CDUS) becoming an established 
alternative. CDUS has a lower sensitivity and specificity for 
endoleaks detection compared to CTA. Contrast-enhanced 
ultrasound scan (CEUS) represents an improvement of 
ultrasound imaging but comparisons against CTA report 
widely varying results, likely due to technical factors 
of CEUS and limitations of single-phase CTA. The 
development of time-resolved CTA (tCTA) offers timing 
information that much more closely mirrors the dynamic 
information available from CEUS. Theoretically, these two 
imaging modalities have the best potential for diagnostic 
accuracy. The aim of this study will be to compare CEUS 
to tCTA and investigate the utility of other measurements 
available from tCTA.
Methods and analysis This is a prospective, single UK 
centre, comparative study of paired binary diagnostic 
imaging modalities. Patients identified in routine post-EVAR 
surveillance as at risk of having a graft-related endoleak 
will undergo a CEUS and tCTA on the same day. This will 
allow the first comparison of CEUS to a semidynamic 
form of CTA. CEUS sensitivity and specificity to endoleak 
detection will be calculated.
Ethics and dissemination The study has achieved ethical 
approval. We hope the results will define the diagnostic 
accuracy of CEUS in comparison to a semidynamic form 
of CTA, representing a methodological improvement from 
previous studies. Results will be submitted for presentation 
at national and international vascular surgeryandradiology 
meetings. The full results are planned to be published in a 
medical journal.
trial registration number NCT02688751.
IntroduCtIon 
background and rationale
Endovascular aneurysm repair (EVAR) is the 
intervention of choice to treat abdominal 
aortic aneurysms (AAA).1 In comparison to 
open surgical repair, EVAR confers a reduc-
tion of mortality lasting into the short to 
intermediate term.2 However, EVAR is asso-
ciated with complications which sometimes 
require secondary interventions in order to 
maintain efficacy of EVAR. This has been 
recognised since the inception of the tech-
nique and confirmed in observational studies 
as well as randomised controlled trials.3–6 
Therefore, periodic surveillance imaging is 
recommended for life following EVAR.7 8 The 
strengths and limitations of this study
 ► First comparison of contrast-enhanced ultrasound to 
a dynamic form of CT imaging, representing a meth-
odological improvement.
 ► Both imaging modalities occur on the same day re-
moving changing findings as a confounding factor.
 ► Primary outcome set as type I/III endoleak (most 
clinically significant) rather than all endoleaks.
 ► Appropriately powered but small study.
 ► Single-centre study.
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importance of post-EVAR surveillance remains enduring, 
its value further highlighted by a recently published anal-
ysis of 15-year follow-up after EVAR.2 
The most common complication in EVAR surveillance 
is an endoleak,9 which is ‘persistent blood flow within the 
aneurysm sac but outside the stent graft’.10 Endoleaks are 
classified based on the source of blood flow,10 but can 
be grouped into stent graft related (types I and III) and 
type II (non-stent graft related) endoleaks. Stent graft-re-
lated endoleaks generally transmit high pressure causing 
a high risk of aneurysm expansion/rupture (treatment 
failure).11 12 In contrast, type II endoleaks generally run 
a benign course, particularly in the absence of aneurysm 
expansion.12 With regard to endoleak imaging, high sensi-
tivity of detection and high specificity of characterisation 
improve diagnostic utility of surveillance, in particular 
with an emphasis on distinguishing stent graft-related 
endoleaks from type II endoleaks. Digital subtraction 
angiography in multiple planes and a high frame rate 
of acquisition is the gold standard of endoleak imaging; 
high frame rates to demonstrate endoleak heamody-
namics for better characterisation. However, this modality 
is not tenable to be used as surveillance imaging.
Historically, EVAR surveillance was undertaken using 
CT angiography (CTA). Arterial phase CT was the most 
frequently used modality although, selectively or routinely 
additional phases are used such as unenhanced, venous 
phase and even delayed phase. Concerns over cost, use 
of potentially nephrotoxic contrast agent and repeated 
radiation exposure led to alternative imaging modali-
ties being investigated and implemented in surveillance 
regimens. Colour duplex ultrasound scan (CDUS) is the 
most widely used imaging modality currently.13 CDUS 
is reported to have a lower sensitivity and specificity to 
detect stent graft-related endoleaks compared with CTA.14
Contrast-enhanced ultrasound scan (CEUS) has 
been investigated as an adjunct to CDUS in the hope 
of improving sensitivity to endoleak detection. CEUS 
involves intravenous injection of a microbubble contrast 
which remains in the blood, allowing improved detection 
of endoleaks, particularly with contrast coherent ultra-
sound imaging. CEUS also allows continuous (dynamic) 
or real-time monitoring of the aneurysm and endoleak 
as the contrast agent arrives into the endoleak. Modern 
microbubble agents are expired by the respiratory system, 
thus avoiding nephrotoxicity. A recent review of 30 222 
administrations of a CEUS contrast agent demonstrated a 
low adverse reaction rate of 0.020%.15 CEUS also obviates 
the radiation exposure associated with CTA. 3D acquisi-
tion and reconstructions of CEUS scans are possible16; 
however, this development in the technology is currently 
limited to single phases of acquisition and therefore losses 
the dynamic information available in standard CEUS.
Systematic review of the diagnostic accuracy of CEUS 
(in comparison to CTA) in detection of any endoleak 
revealed variable sensitivity ranging from 67% to 100% 
and specificity ranging from 79% to 100%.17 The value of 
this review is compromised by heterogeneity of contrast 
material used and non-reporting of ultrasound imaging 
technique used, specifically whether colour duplex 
combined with contrast or harmonic CEUS imaging was 
used. There are potentially additional reasons for vari-
ability in the reporting such as operator dependence, 
quality of equipment used as well as body habitus of the 
patient. The consideration that neither CEUS nor single-
phase CTA represent gold standard of endoleak diagnosis 
led to the metanalysis14 17 adopting a bivariate model of 
analysis. This approach does not compensate for the lack 
of gold standard comparator as it favours any modality 
producing false positives. Comparison against the gold 
standard has never been established for either modality.
time-resolved CtA
Time-resolved CTA (tCTA) was first described for 
endoleak detection in 201018. The single arterial phase is 
replaced by multiple phases in tCTA, which are typically 
of lower radiation dose, thus offering dynamic observa-
tions of endoleaks, such as flow direction and filling 
speed, while still retaining many of the advantages of CTA 
(3D reconstruction, etc) which closely mirror the advan-
tages of the multiplanar digital subtraction catheter angi-
ography. The multiple phases of tCTA can be achieved 
by broad CT detectors and a static patient in the Fowler 
position19 or rapid shuttling of a supine patient through a 
standard detector.20 21 Sufficient amount of measurements 
regarding filling patterns of endoleaks on tCTA21 are now 
available to be able to replace a standard arterial phase in 
CTA with a tCTA that is aimed at detecting stent graft-re-
lated endoleaks, without increasing radiation exposure 
for the patient. Now timings and interpretation of tCTA 
are understood it is timely to do a comparison of CEUS 
to the improved comparator of tCTA. This overcomes the 
limitations of previous studies by comparison of CEUS to 
a (semi)dynamic form of CTA imaging as a gold standard.
MEthods
study design
This is a prospective single-centre comparative study of 
paired diagnostic imaging modalities, designed to comply 
with the ‘standards for reporting diagnostic accuracy 
studies’.22 23 Participants will be recruited from a city-wide 
vascular service in the UK. The service is arranged in a 
hub and spoke configuration locally and regularly accepts 
tertiary referrals for complications of previous aortic 
surgery at other centres. EVAR surveillance is predomi-
nately undertaken using CDUS and plain radiography.24
Participants
Potential participants are referred to the study by their 
vascular surgeon when they require a CTA for further 
investigations of an endoleak following routine EVAR 
surveillance and meet inclusion criteria (box 1). They 
are typically patients with a suspicion of a graft-related 
endoleak or aneurysm expansion on CDUS surveillance. 
They are then assessed by the study for eligibility based on 
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exclusion criteria (box 2) and approached to participate 
in the study, if appropriate. Patients are approached by 
an investigator and those who give their written informed 
consent to participate will be enrolled in the study.
test methods
Participants attend and have a CEUS (index test) 
and tCTA (reference standard) on the same day. This 
represents a change from standard care for participants 
who would otherwise have a CEUS and triple phase CTA 
(non-contrast, arterial (20 s) and delayed venous phase 
(90 s)) often on separate days. Participants will also be 
asked a short number of closed questions to assess func-
tional status and cardiac function (online Supplementary 
material). On completion of the CEUS and tCTA, partic-
ipants are returned to their referring surgeons, with clin-
ical reports of the studies for ongoing care. The study 
team follows the participants’ further treatment and 
investigation until the end of the study.
Contrast-enhanced ultrasound
CEUS is performed in combination with a standard 
CDUS in our institution. It is reported as a binary test 
yielding two values: present or absent for each endoleak 
type. It is conducted by an experienced clinical vascular 
scientist with extensive involvement in scans for EVAR 
surveillance. It is performed on a Philips IU22 ultrasound 
machine (Philips, Amsterdam, Netherlands), using the 
a 2–5 MHz abdominal curved array probe. Grey-scale 
images of the aneurysm neck (when possible), iliac seal 
zones and maximum aneurysm dimensions are obtained 
and measured in maximum anteroposterior and medio-
lateral dimensions. Note is made of the echogenicity of 
thrombus within the aneurysm sac. Using colour flow 
imaging and spectral Doppler, waveform characteris-
tics and velocities are recorded in the common femoral 
arteries. The stent graft is interrogated using colour and 
spectral Doppler to ascertain patency and flow heamo-
dynamics of the neck, main body and both limbs. Any 
abnormalities in these parameters are reported. Colour 
Doppler is used to detect any endoleak. If present, its 
type, point of inflow, point of outflow and flow dynamics 
(using sectoral Doppler) are reported.
Optimum views of the area of concern are obtained, 
prior to contrast injection, using appropriate machine 
set-ups and controls as determined by the operator. 
Sulphur hexafluoride microbubble contrast (2.4 mL; 
SonoVue, Bracco, Milan, Italy) is injected followed by 
10 mL of sodium chloride 0.9%; the on-screen timer is 
started at the start of the injection. Flow direction and 
filling time ideally should be determined and anatomy of 
the endoleak established by interrogation. Passive elimi-
nation of the contrast agent is allowed to occur and the 
process repeated for a second injection.
CEUS scan will be reported by the performing vascular 
scientist to the data point recorded in the data collection 
pro forma (online Supplementary material), in addition 
to any clinically relevant points. The vascular scientist 
will be blinded to the concurrent tCTA at the time of 
reporting, although will be aware of the previous findings 
on EVAR surveillance.
time-resolved CtA
tCTA is performed on a Siemens Definition AS+scanner 
(Seimens, Munich, Germany), in our institution. Partici-
pants are positioned supine with arms raised above their 
head. The contrast injector is connected to a 20 G (or 
larger) intravenous catheter in an anterior cubital fossa 
vein. A standard topogram scan is performed. Unless 
not required, a non-contrast scan is performed. The 
maximum length that can be covered for the time reso-
lution required is 27 cm. This is centred over the EVAR 
stent graft. Abdominal guides are placed at upper aspect 
of diaphragm and common femoral arteries for venous 
phase of scan. Abdominal aorta, just proximal to EVAR 
graft is selected as trigger area for time-resolved phases.
Contrast is injected, using an auto injector, at 4 mL/s 
for 96 mL. Participants are asked to adopt shallow breaths 
and not hold their breath. The time-resolved phase is 
triggered by a Hounsfield unit (HU)>90 in trigger area. 
Phases occur at 2.5, 5, 7.5, 10, 15, 20 and 25 s following 
the automatic trigger; these occur in craniocaudual 
acquisition, except the 5 and 7.5 s phases which occur in 
a caudocranial direction. The venous phase is taken in 
full inspiration and is acquired 75 s following the trigger. 
Tube setting and calculated predicted radiation exposure 
are presented in table 1.
All tCTA scans will be reported by a single consultant 
vascular radiologist. This reporter will be blinded to the 
box 1 Inclusion criteria
 ► Aged 18 or over.
 ► Able to give informed consent.
 ► Undergone an endovascular aneurysm repair (EVAR) of infrarenal 
abdominal aortic aneurysm.
 ► Planned for CT angiography of EVAR.
box 2 Exclusion criteria
 ► Unable to receive CT angiography (CTA) contrast
 – Allergy.
 – Insufficient renal function for standard outpatient contrast study 
(estimated glomerular filtration rate <45).
 – Overactive thyroid gland.
 ► Unable to receive contrast-enhanced ultrasound scan contrast
 – Previous reaction to Sonovue®  (ultrasound contrast).
 – Allergy to sulphur hexafluoride (used in electrical industry in cir-
cuit breakers, switch gears and electrical equipment).
 – Recent acute coronary syndrome or unstable angina, typical an-
gina at rest or frequent or repeated angina/chest pain—all within 
previous 7 days.
 – Recent coronary intervention.
 ► Previous embolisation of artery in region of endovascular aneurysm 
repair (affects imaging quality).
 ► Body mass index >30 (affects imaging quality).
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results of the CEUS and collect data to the pro forma. 
It will be reported as a binary test yielding two values: 
present or absent for each type of endoleak.
outcome measures
The primary outcome is:
1. The predictive values of CEUS in comparison to 
tCTA (as comparator) to detect stent graft-related 
endoleaks.
Secondary outcomes are:
1. Any adverse events during CEUS or tCTA.
2. Predictive values of CEUS in comparison to tCTA to 
detect type II endoleaks.
3. Predictive values of both tCTA and CEUS in predict-
ing final endoleak diagnosis (following any further 
investigations).
4. Predictive values of both tCTA and CEUS in predict-
ing need for a secondary intervention.
5. Evaluate the association between CEUS temporal 
delay (difference between contrast in endograft and 
contrast in endoleak) and evaluate its ability to im-
prove the differentiation of endoleak type.
6. Evaluate the association between ‘CEUS contrast in 
endoleak’ to ‘tCTA contrast in endoleak’ and assess 
potential as predictive tool, for optimum timing of 
CTA phases.
Analysis plan
Associations will be established/refuted with summary 
statistics and graphical analysis and appropriate further 
statistical testing within the framework of logistic regres-
sion. If association can be established, then predictive 
modelling will be undertaken. The agreement between 
CEUS and tCTA will be evaluated with Kappa statistic.25 
Sensitivity/specificity will be calculated along with bino-
mial exact 95% CIs and leave-one-out cross-validation. We 
will also report the positive predictive value and negative 
predictive value.
The power calculation26 showed the required sample 
size to be 74. This was calculated based on a prevalence 
of stent graft-related endoleaks of 11% as demonstrated 
on previous tCTA studies of endoleaks. It was powered to 
detect a predicted sensitivity of 0.95 with a tolerated CI 
of ±0.15. The study commenced recruitment in February 
2016 and is ongoing.
Monitoring and data
All patients referred to the study are recorded in 
the screening log. The sponsoring trust will provide 
governance oversight and annual reports to the 
ethics committee will provide ethical overview. Radiation 
exposure of participants will be monitored and reported 
to the sponsors and approving research ethics committee. 
No interim analysis is planned.
On completion of the study, all identifiable patient 
demographics will be removed and anonymised data will 
be stored to allow for future analysis of unforeseen bene-
fits. During the study, data are stored in a secure manner 
within the host institutions data management processes. 
Access is restricted to the investigators and for audit by 
the sponsor.
Ethics and dissemination
The main ethical consideration is the change of care 
from CTA to a tCTA; this was felt to be appropriate in the 
context of informed consent, now it can be performed 
without increasing radiation exposure. Ethical approval 
(15/NW/0908) was granted by a National Health Service 
Research Ethics Committee. On completion of analysis, 
we expect to publish in a medical journal, along with the 
anonymised data set and present the findings widely.
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Table 1 Settings and radiation exposure from arterial and 
time-resolved phases of CT angiography
Arterial phase 
(outside study)
Time-resolved 
phases (inside study)
Tube  voltage 120 kV  80 kV
Tube  current 230 mA (effective 
current–scanner 
automatically 
varies)
 120 mA
Scan  l ength Variable (dependant 
on body length)
 27 cm
Number of 
Phases
One Seven
Expected DLP 599.6*  78.9 mGy/cm per 
phase (552.3 mGy/
cm for time-resolved 
phase)
*Average DLP used for an arterial phase scan in all CT angiography 
scans in Royal Liverpool Hospital in month of July 2015. 
DLP, Dose Length Product.
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